Epix Finally Sells Vasovist and Flips Debt, But Will It Escape Bankruptcy?
This article was originally published in The Pink Sheet Daily
Executive Summary
Marrying off drugs inherited in Predix merger could help firm stay afloat.
You may also be interested in...
Gadolinium Imaging Agents To Get Safety Review At FDA Advisory Committee
Sponsors are conducting mandatory clinical trials on the risk for patients with moderate to severe renal insufficiency.
Gadolinium Imaging Agents To Get Safety Review At FDA Advisory Committee
Sponsors are conducting mandatory clinical trials on the risk for patients with moderate to severe renal insufficiency.
Business And Finance In Brief
Bristol says Lilly's Effient no match for Plavix: Bristol-Myers Squibb doesn't "think we need to put more or less resources behind Plavix (clopidogrel) because of the imminent launch of Effient," President and Chief Operating Officer Lamberto Andreotti said in response to analysts' questions about expected competition to its star drug from Lilly/Daiichi Sankyo's newly approved anti-coagulant Effient (prasugrel), during a July 23 earnings call. Bristol-Myers Squibb stressed that Plavix has a broader range of use compared to Effient. More than that, Andreotti said, he's not saying, though he did mention Effient's black box warning in the label. Plavix (sales up 15 percent U.S. to $1.39 billion in Q2), which isn't encumbered by a black box warning, is indicated to reduce atherothrombotic events in patients with recent stroke, myocardial infarction, established peripheral arterial disease and for use in acute coronary syndrome. Effient was approved to reduce thrombotic cardiovascular events in ACS patients who are to be managed with percutaneous coronary intervention (1"The Pink Sheet" DAILY, July 10, 2009)